Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| NO2 - derivatives | 4797 | 7632-00-0 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Nitrous acid sodium salt. Used in many industrial processes, in meat curing, coloring, and preserving, and as a reagent in ANALYTICAL CHEMISTRY TECHNIQUES. It is used therapeutically as an antidote in cyanide poisoning. The compound is toxic and mutagenic and will react in vivo with secondary or tertiary amines thereby producing highly carcinogenic nitrosamines.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 14, 2011 | FDA | HOPE PHARMS |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | V03AB08 | VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Antidotes |
| MeSH PA | D005503 | Food Additives |
| MeSH PA | D005520 | Food Preservatives |
| MeSH PA | D007202 | Indicators and Reagents |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35674 | antihypertensive agent |
| CHEBI has role | CHEBI:38068 | antimalarial |
| CHEBI has role | CHEBI:64909 | poison |
| CHEBI has role | CHEBI:65023 | anti-asthmatic agent |
| CHEBI has role | CHEBI:65256 | antimicrobial food preservative |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| CHEBI has role | CHEBI:77962 | food antioxidant |
| CHEBI has role | CHEBI:90749 | antidote to cyanide poisoning |
| CHEBI has role | CHEBI:176497 | geroprotector |
| CHEBI has role | CHEBI:231911 | renoprotective agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Toxic effect of cyanide | indication | 66207005 |
None
None
None
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML) | NITHIODOTE | HOPE PHARMS | N201444 | Jan. 14, 2011 | RX | SOLUTION, SOLUTION | INTRAVENOUS, INTRAVENOUS | 11753301 | Feb. 10, 2030 | TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE SERIOUS OR LIFE-THREATENING |
| 300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML) | NITHIODOTE | HOPE PHARMS | N201444 | Jan. 14, 2011 | RX | SOLUTION, SOLUTION | INTRAVENOUS, INTRAVENOUS | 9687506 | Feb. 10, 2030 | SODIUM NITRITE INJECTION IS ADMINISTERED BY INTRAVENOUS INJECTION |
| 300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML) | NITHIODOTE | HOPE PHARMS | N201444 | Jan. 14, 2011 | RX | SOLUTION, SOLUTION | INTRAVENOUS, INTRAVENOUS | 9687506 | Feb. 10, 2030 | SODIUM NITRITE INJECTION IS INDICATED FOR SEQUENTIAL USE WITH SODIUM THIOSULFATE FOR THE TREATMENT OF ACUTE CYANIDE POISONING |
| 300MG/10ML (30MG/ML) | SODIUM NITRITE | HOPE PHARMS | N203922 | Feb. 14, 2012 | RX | SOLUTION | INTRAVENOUS | 9687506 | Feb. 10, 2030 | SODIUM NITRITE INJECTION IS ADMINISTERED BY INTRAVENOUS INJECTION |
| 300MG/10ML (30MG/ML) | SODIUM NITRITE | HOPE PHARMS | N203922 | Feb. 14, 2012 | RX | SOLUTION | INTRAVENOUS | 9687506 | Feb. 10, 2030 | SODIUM NITRITE INJECTION IS INDICATED FOR SEQUENTIAL USE WITH SODIUM THIOSULFATE FOR THE TREATMENT OF ACUTE CYANIDE POISONING |
| 300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML) | NITHIODOTE | HOPE PHARMS | N201444 | Jan. 14, 2011 | RX | SOLUTION, SOLUTION | INTRAVENOUS, INTRAVENOUS | 10479686 | July 7, 2030 | SODIUM THIOSULFATE INJECTION IS ADMINISTERED BY INTRAVENOUS INJECTION |
| 300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML) | NITHIODOTE | HOPE PHARMS | N201444 | Jan. 14, 2011 | RX | SOLUTION, SOLUTION | INTRAVENOUS, INTRAVENOUS | 9345724 | July 7, 2030 | SODIUM THIOSULFATE INJECTION IS INDICATED FOR SEQUENTIAL USE WITH SODIUM NITRITE FOR THE TREATMENT OF ACUTE CYANIDE POISONING |
| 300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML) | NITHIODOTE | HOPE PHARMS | N201444 | Jan. 14, 2011 | RX | SOLUTION, SOLUTION | INTRAVENOUS, INTRAVENOUS | 8496973 | March 29, 2031 | TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING |
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Carbonic anhydrase 2 | Enzyme | Ki | 1.20 | CHEMBL | |||||
| Carbonic anhydrase 1 | Enzyme | Ki | 2.08 | CHEMBL | |||||
| Carbonic anhydrase 13 | Enzyme | Ki | 1.90 | CHEMBL |
| ID | Source |
|---|---|
| M0KG633D4F | UNII |
| D05865 | KEGG_DRUG |
| 4017515 | VUID |
| N0000145900 | NUI |
| 4017515 | VANDF |
| C0037532 | UMLSCUI |
| CHEBI:78870 | CHEBI |
| CHEMBL93268 | ChEMBL_ID |
| 23668193 | PUBCHEM_CID |
| D012977 | MESH_DESCRIPTOR_UI |
| 9894 | RXNORM |
| 47919 | MMSL |
| 5488 | MMSL |
| d04086 | MMSL |
| 000682 | NDDF |
| 10377000 | SNOMEDCT_US |
| 317873006 | SNOMEDCT_US |
| M0KG633D4F | INXIGHT DRUGS |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Sodium Nitrite | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60267-311 | INJECTION, SOLUTION | 30 mg | INTRAVENOUS | NDA | 28 sections |
| Sodium Nitrite | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60267-311 | INJECTION, SOLUTION | 30 mg | INTRAVENOUS | NDA | 28 sections |